Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

A trial to test a new path for preventing Alzheimer’s

Alzheimer research made a breakthrough last month when Eli Lilly's drug donanemab slowed cognitive decline in 47% of those taking it. It follows two other drugs, lecanemab and aducanumab, that target amyloid protein buildup in the brain. However, these drugs can cause fatal brain bleeding and seizures. Oxidative stress hypothesis…

The Hindu

Why This Nugget Of Bad Weight-Loss News Isn't Weighing On Lilly, Novo

Prescriptions of weight-loss and diabetes drugs have rocketed this year, giving Novo Nordisk stock and Eli Lilly stock more room to run.

Investors Business Daily

Insulin Patients Can Find Discounts With Amazon's New Automated Coupon System

Amazon Pharmacy will automatically apply manufacturer-sponsored coupons for 15-plus products.

Kiplinger

From analysis to the latest developments in health,
read the most diverse news in one place.

Market Rally On The Ropes, AI Stocks Tumble: Weekly Review

The market rally suffered more damage as the Nasdaq undercut key support and many leading AI stocks sold off hard.

Investors Business Daily

Eli Lilly Reverses Its Recent Upswing On Broader Market Woes. Is It A Sell?

Eli Lilly stock has sold off alongside the broader market over the last week, undercutting its moving averages. Is LLY stock a sell?

Investors Business Daily

Tesla Hires New Exec To Lead Giga Nevada's Massive $3.6B Expansion

Before joining Tesla in July, Michael Hildebrand was executive director of projects at Eli Lilly, where he spent the previous 19 years of his career.

InsideEVs

Dow Jones Futures Rise After Market Rally Holds Support; Two Big AI Losers

The market rally faces a key test. Nvidia is holding strong, but some Magnificent 7 stocks are ailing. Two AI plays dived late.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Stock Market Today: Stocks Drop on Troubling China Data, Bank Ratings Worries

The main benchmarks fell Tuesday, but healthcare stocks outperformed as Eli Lilly and Novo Nordisk surged.

Kiplinger

Soaring sales of diabetes drug Mounjaro, often used for weight loss, sends Eli Lilly to new heights

Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected

The Independent UK

Eli Lilly Surges 15% After Diabetes Powerhouse Mounjaro Fuels Beat And Raise

Eli Lilly stock broke out bullishly Tuesday after the drugmaker walloped forecasts partly due to diabetes treatment powerhouse Mounjaro.

Investors Business Daily

Dow Jones Dives 450 Points On Moody's Bank Downgrades; Palantir Plunges On Earnings

The Dow Jones Industrial Average dived 450 points Tuesday on Moody's bank downgrades. Hot AI stock Palantir Technologies dived on second-quarter earnings results.

Investors Business Daily

Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor

Drugmaker Novo Nordisk focuses on Black lawmakers and opinion leaders to spread the message that obesity is a chronic disease — worth treating at a cost of $1,000 or more a month.

WEKU

AI Stock Marvell And Eli Lilly Lead 5 Names Near Buy Points As S&P 500 Rallies On

Top AI stock Marvell Technology and Eli Lilly lead this weekend's watch list of five stocks near buy points as the new S&P 500 bull market revs back up.

Investors Business Daily

Biogen Stock Tumbles On Plans To Cut 11% Of Workforce; Tops Second-Quarter Estimates

Biogen stock dropped Tuesday after the biotechnology firm said it's eliminating 1,000 jobs as part of a strategy to cut operating expenses.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Conversation

The obesity epidemic is fuelled by biology, not lack of willpower

Since the time a human first used a tool to make life easier, increased weight has been inevitable.

Investors Business Daily

IBD Stock Of The Day Novo Nordisk, A Weight-Loss Kingpin, Just Retook Its 50-Day Line

Novo Nordisk stock is Thursday's IBD Stock Of The Day. Shares bounded above their 50-day line, giving investors a new entry.

The Conversation

Alzheimer's drug donanemab has been hailed as a 'turning point' for treatment. But what does it mean for people with the disease?

Trial results of a new drug to treat Alzheimer’s disease, donanemab, shows it can slow cognitive decline by 35%. The drug has been hailed as a “turning point” in Alzheimer’s treatment.

Investors Business Daily

Dow Jones Futures Rise After Market Rallies On Microsoft AI Push; Netflix, Tesla Earnings On Tap

Microsoft AI pricing fueled the Nasdaq, which is increasingly extended. Netflix and Tesla earnings loom.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Microsoft, Eli Lilly Bolster Stock Market Upside; This Sector Is Smashing The Dow Jones Industrial Average's Performance

ARCB also is trying to storm past a cup with handle that shows a 101.49 buy point.

Investors Business Daily

IBD Stock Of The Day Eli Lilly: How Alzheimer's And Weight Loss Are Driving A New Breakout

Eli Lilly stock is Tuesday's IBD Stock Of The Day. Shares are rising as Lilly's Alzheimer's treatment appears "very competitive" with Biogen's.

StockNews.com

Should Investors Start Watching Eli Lilly & Co. (LLY) This Week?

Despite macroeconomic headwinds dampening the growth of various industries, Eli Lilly and Company (LLY) has remained resilient and is ramping up investments in medical research. So, will it be a good watchlist addition this week? Keep reading.

The Independent UK

New drug found to slow Alzheimer’s hailed as turning point

Donanemab has been found to slow down the disease in a clinical trial.

The Independent UK

Everything we know about breakthrough Alzheimer’s drug Donanemab

Alzheimer’s disease is the most common cause of dementia in the UK

Evening Standard

Alzheimer’s: ‘Turning point’ in fight against disease as drug found to slow decline by up to 35%

Experts say ‘we’re entering a new era where Alzheimer’s disease could become treatable’

The Guardian - UK

Experts urge health regulators to approve ‘turning point’ dementia drugs

Exclusive: As results show 35% slowing in cognitive decline, health leaders say swift decisions crucial

1 … 17 18 19 20

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations